• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1型糖尿病患者中非酒精性脂肪性肝病(NAFLD)的患病率及其与胰岛素抵抗替代指标的关联。

Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes.

作者信息

de Vries Marieke, Westerink Jan, El-Morabit Fatima, Kaasjager H A H Karin, de Valk Harold W

机构信息

Department of Internal Medicine, Diabetology and Vascular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.

Department of Gastroenterology, University Medical Center Utrecht, Utrecht, the Netherlands.

出版信息

Diabetes Res Clin Pract. 2022 Apr;186:109827. doi: 10.1016/j.diabres.2022.109827. Epub 2022 Mar 10.

DOI:10.1016/j.diabres.2022.109827
PMID:35283265
Abstract

AIMS

Assess prevalence of hepatic steatosis (HS) and of fibrosis in an unselected population of patients with type 1 diabetes. Describe their clinical profile and explore the association between insulin resistance and NAFLD as secondary objectives.

METHODS

We prospectively assessed NAFLD by transient elastography in adult outpatients with type 1 diabetes. Patients were eligible if they did not have any known secondary cause of liver disease. NAFLD was defined as HS with or without fibrosis/cirrhosis. Associations between estimated glucose disposal rate (eGDR) and metabolic syndrome, as surrogate markers of insulin resistance, and NAFLD were explored using multivariate logistic regression models, adjusting for age, sex and diabetes duration.

RESULTS

We enrolled 150 consecutive subjects (age 47 ± 14 years, male 55%, diabetes duration 25 ± 14 years, median BMI 25 kg/m). NAFLD prevalence was 20% (n = 30). Thirty patients (20%) had HS. Five patients (3.3%) had HS with fibrosis. eGDR and metabolic syndrome were statistically significantly associated with the presence of NAFLD (OR 0.62, 95% CI 0.49-0.77, OR 7.62, 95% CI 2.95-19.77).

CONCLUSIONS

NAFLD prevalence in patients with type 1 diabetes is considerable, mainly restricted to isolated HS, while fibrosis is rare. Insulin resistance is associated with NAFLD in patients with type 1 diabetes.

摘要

目的

评估1型糖尿病患者未经过挑选的人群中肝脂肪变性(HS)和纤维化的患病率。描述其临床特征,并将胰岛素抵抗与非酒精性脂肪性肝病(NAFLD)之间的关联作为次要目标进行探究。

方法

我们采用瞬时弹性成像技术对成年1型糖尿病门诊患者的NAFLD进行前瞻性评估。如果患者没有任何已知的继发性肝病病因,则符合入选标准。NAFLD定义为伴有或不伴有纤维化/肝硬化的HS。使用多因素逻辑回归模型,在调整年龄、性别和糖尿病病程后,探究估计葡萄糖处置率(eGDR)和代谢综合征(作为胰岛素抵抗的替代指标)与NAFLD之间的关联。

结果

我们连续纳入了150名受试者(年龄47±14岁,男性占55%,糖尿病病程25±14年,BMI中位数为25kg/m²)。NAFLD患病率为20%(n = 30)。30名患者(20%)有HS。5名患者(3.3%)有伴有纤维化的HS。eGDR和代谢综合征与NAFLD的存在在统计学上显著相关(OR 0.62,95%CI 0.49 - 0.77,OR 7.62,95%CI 2.95 - 19.77)。

结论

1型糖尿病患者中NAFLD的患病率相当可观,主要局限于单纯性HS,而纤维化很少见。胰岛素抵抗与1型糖尿病患者的NAFLD相关。

相似文献

1
Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes.1型糖尿病患者中非酒精性脂肪性肝病(NAFLD)的患病率及其与胰岛素抵抗替代指标的关联。
Diabetes Res Clin Pract. 2022 Apr;186:109827. doi: 10.1016/j.diabres.2022.109827. Epub 2022 Mar 10.
2
Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes.非酒精性脂肪性肝病:1型和2型糖尿病患者相同的病因因素
Eur J Intern Med. 2022 Jun;100:77-82. doi: 10.1016/j.ejim.2022.03.025. Epub 2022 Apr 3.
3
Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients.代谢综合征、非酒精性脂肪性肝病与银屑病关节炎及银屑病患者的肝硬度。
Clin Rheumatol. 2019 Oct;38(10):2843-2850. doi: 10.1007/s10067-019-04646-7. Epub 2019 Jun 28.
4
Association of physical activity and sports participation with insulin resistance and non-alcoholic fatty liver disease in people with type 1 diabetes.1 型糖尿病患者身体活动和运动参与与胰岛素抵抗和非酒精性脂肪肝的关系。
Diabet Med. 2024 Jul;41(7):e15317. doi: 10.1111/dme.15317. Epub 2024 Apr 8.
5
Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.经瞬时弹性成像定义的非酒精性脂肪性肝病患者中显著纤维化的患病率及预测因素
Dig Dis Sci. 2017 Aug;62(8):2150-2158. doi: 10.1007/s10620-017-4592-0. Epub 2017 May 18.
6
Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients.2 型糖尿病患者非酒精性脂肪性肝病相关肝纤维化的危险因素。
Acta Diabetol. 2019 Nov;56(11):1199-1207. doi: 10.1007/s00592-019-01374-x. Epub 2019 Jun 13.
7
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.美国非酒精性脂肪性肝炎相关肝硬化的患病率:基于国家健康与营养检查调查数据的分析
Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14.
8
Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.摩洛哥人群中非酒精性脂肪性肝病(NAFLD)和 2 型糖尿病的流行情况及其具体表现:一项横断面研究。
Rev Diabet Stud. 2022 Sep 28;18(3):140-145. doi: 10.1900/RDS.2022.18.140.
9
Indirect insulin resistance markers are associated with nonalcoholic fatty liver disease in type 1 diabetes.间接胰岛素抵抗标志物与 1 型糖尿病中非酒精性脂肪性肝病相关。
Pol Arch Intern Med. 2023 May 23;133(5). doi: 10.20452/pamw.16404. Epub 2023 Jan 5.
10
Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.非酒精性脂肪性肝病在糖尿病患者中的临床谱。
PLoS One. 2020 Aug 21;15(8):e0236977. doi: 10.1371/journal.pone.0236977. eCollection 2020.

引用本文的文献

1
Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes.1型糖尿病患者的代谢功能障碍相关脂肪性肝病
J Clin Med. 2025 Aug 5;14(15):5502. doi: 10.3390/jcm14155502.
2
Association of estimated glucose disposal rate with risk of future metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases: a prospective cohort study.估计葡萄糖处置率与未来代谢功能障碍相关脂肪性肝病及其他慢性肝病风险的关联:一项前瞻性队列研究
Front Med (Lausanne). 2025 Jul 2;12:1589245. doi: 10.3389/fmed.2025.1589245. eCollection 2025.
3
Association between eGDR and MASLD and liver fibrosis: a cross-sectional study based on NHANES 2017-2023.
估算肾小球滤过率与代谢相关脂肪性肝病及肝纤维化之间的关联:一项基于2017 - 2023年美国国家健康与营养检查调查的横断面研究。
Front Med (Lausanne). 2025 May 30;12:1579879. doi: 10.3389/fmed.2025.1579879. eCollection 2025.
4
Factors Associated With Advanced Liver Fibrosis in a Population With Type 2 Diabetes: A Multicentric Study in Mexico City.2型糖尿病患者中与晚期肝纤维化相关的因素:墨西哥城的一项多中心研究
J Clin Exp Hepatol. 2025 Jul-Aug;15(4):102536. doi: 10.1016/j.jceh.2025.102536. Epub 2025 Feb 27.
5
A negative correlation of low estimated glucose disposal rate with significant liver fibrosis in adults with NAFLD and obesity: results from NHANES 2017-2020.非酒精性脂肪性肝病(NAFLD)和肥胖成人中,低估计葡萄糖处置率与显著肝纤维化呈负相关:2017 - 2020年美国国家健康与营养检查调查(NHANES)结果
BMC Gastroenterol. 2025 Mar 29;25(1):206. doi: 10.1186/s12876-025-03798-y.
6
Converging Pathways between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Diabetes in Children.代谢功能障碍相关脂肪性肝病(MASLD)与儿童糖尿病之间的交汇途径。
Int J Mol Sci. 2024 Sep 14;25(18):9924. doi: 10.3390/ijms25189924.
7
Type 1 diabetes and combined acute and chronic complications are associated with risk of progression of liver fibrosis: a Mendelian randomization study.1 型糖尿病及其合并的急慢性并发症与肝纤维化进展风险相关:一项孟德尔随机研究。
Front Endocrinol (Lausanne). 2024 Aug 5;15:1302611. doi: 10.3389/fendo.2024.1302611. eCollection 2024.
8
Associations between estimated glucose disposal rate and arterial stiffness and mortality among US adults with non-alcoholic fatty liver disease.美国非酒精性脂肪性肝病患者中估计葡萄糖处置率与动脉僵硬度和死亡率之间的关系。
Front Endocrinol (Lausanne). 2024 May 8;15:1398265. doi: 10.3389/fendo.2024.1398265. eCollection 2024.
9
Retinal Vascular Lesions in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.非酒精性脂肪性肝病患者的视网膜血管病变:系统评价与荟萃分析
J Pers Med. 2023 Jul 17;13(7):1148. doi: 10.3390/jpm13071148.
10
Prevalence, risk factors and diagnostic accuracy of non-invasive tests for NAFLD in people with type 1 diabetes.1型糖尿病患者非酒精性脂肪性肝病非侵入性检测的患病率、危险因素及诊断准确性
JHEP Rep. 2023 Apr 7;5(7):100753. doi: 10.1016/j.jhepr.2023.100753. eCollection 2023 Jul.